logo-loader
viewCytoDyn Inc.

CytoDyn sees impressive results with Leronlimab on very ill COVID-19 patients

CytoDyn (OTCQB: CYDY) CEO Dr Nader Pourhassan and IncellDX CEO Dr Bruce Patterson joined Steve Darling from Proactive Vancouver with news that the three-day effect of leronlimab in eight severely ill COVID-19 patients demonstrated a significant improvement in several important immunologic biomarkers.  

Both Dr Patterson and DR Pourhassen tell Proactive about the study and the next major steps they are planning on taking. 
 

Quick facts: CytoDyn Inc.

Price: 3.7599 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $1.95 billion
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CytoDyn to submit request for pre-submission meetings in U.K. for Leronlimab

CytoDyn Inc (OTCQB: CYDY) CEO Nader Pourhassan shared news with Steve Darling from Proactive that the company has started the process of requesting meetings in the U.K. for leronlimab as an HIV treatment as well as for emergency approval of leronlimab for COVID-19 patients with mild-to-moderate...

1 week, 1 day ago

2 min read